The study explored the cost-consequences of adding examination with Hexaminolevulinate (HAL) and blue light in flexible cystoscopy to the regular follow-up regimen during the first year in an outpatient setting in Sweden. All risk groups of bladder cancer (non-muscle invasive) were included in the analysis. In a 5-year perspective, the introduction of HAL BLFC resulted in improved patient outcome and a reduction of hospital resource use with a minimal cost impact. The budget impact was estimated to +1,6% total cost over 5 years, or SEK 189 per patient per year, compared to using standard white light alone.
Read more here